|
Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as interim chief executive officer and Klaas de Boer as a senior advisor to the board. Last month, Andrew Newland stepped down as CEO following talks with an unnamed ‘significant shareholder’. Notes Collins’ over 25 years of experience in oncology and diagnostics development. ‘Peter is an exceptional leader with a proven track record of commercial excellence, disciplined execution, and innovation. The board is delighted that he has agreed to serve as interim CEO while we continue the process to make a permanent appointment. We are also delighted to have Klaas assisting the board and management team during the coming period,’ says Executive Chair Jan Groen. Current stock price: 1.75 pence, down 7.9% on Thursday afternoon in London. 12-month change: down 77% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
